Sanaria, malaria program to begin human trials of novel vaccine

04/23/2009 | American City Business Journals

Biotech firm Sanaria and the Path Malaria Vaccine Initiative are preparing to launch the first human trials of a vaccine that contains a weakened version of an entire malaria parasite found in radiation-zapped mosquitoes. The groups plan to enroll 104 healthy volunteers and expect to treat the first patient in mid-May.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC